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avoided compared with 6-day ﬁ lgrastim for NHL patients treated with CHOP-14, and 
<c7000 for BC patients treated with TAC. Pegﬁ lgrastim dominated 11-day 
ﬁ lgrastim.
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OBJECTIVES: To asses the cost-effectiveness relationship of dasatinib in comparison 
to high dose of imatinib in the treatment of CML in patients with imatinib-resistant 
chronic myeloid leukemia in Spain. METHODS: A Markov model was developed to 
estimate, in the long term, the costs and clinical outcomes (life-years gained and 
quality-adjusted life-years gained) of dasatinib compared to imatinib in imatinib-
resistant patients. Four health states were considered in the analysis: Chronic phase; 
Accelerated phase; Blast phase; and Death. Cycle length is on a monthly basis and 
health effects and costs were counted until all patients reached the “death” health 
state. The efﬁ cacy outcomes are estimated from a direct comparison derived from the 
clinical trial BMS 017. The health-care resource use has been set up by a Spanish 
clinical expert and direct costs are in euros (2009). The perspective used is the Spanish 
Health System. Both costs and effects were discounted annually at 3.5%. The robust-
ness of the results was tested in deterministic sensitivity analyses. RESULTS: In the 
base-case scenario, treatment with dasatinib proves to be a dominant option with a 
lower total cost and a higher level of effectiveness (potential cost saving of c56,995 
and 0.19 QALY gained). The sensitivity analysis indicates that dasatinib remains as 
a dominant alternative in front of changes in the most relevant variables: costs, utility 
values, age at the start of the treatment, time horizon, and discount rate. CONCLU-
SIONS: Compared to imatinib, dasatinib shows a slower disease progression with 
relatively lower direct medical costs. Dasatinib can be regarded as a dominant treat-
ment option in patients with imatinib-resistant CML in the Spanish Health System.
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BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common of adult 
leukemias, comprising about 30–40% of all cases (Watson 2008). Incidence of CLL 
varies worldwide, being 4.3/100,000 in Caucasian men and increases with age, with 
median age at diagnosis of 64–70 years (Yamamoto 2005). In a phase III trial (CLL-8), 
the combined immunochemotherapy R-FC (rituximab plus ﬂ udarabine and cyclophos-
phamide) showed longer progression-free and overall survival, higher complete 
response rate, and longer duration of response than FC alone in previously untreated 
CLL patients. OBJECTIVES: To assess the incremental cost-utility ratio for R-FC 
versus FC alone in untreated CLL patients under the public payer perspective in Brazil. 
METHODS: The cost-effectiveness analysis was based on the pivotal study ML17102 
(CLL-8). a Markov model was developed consisting of three health states: “Progres-
sion-Free Survival” (PFS), “Progression,” and “Death”. The model cycle length is 
monthly and the time horizon of the analysis is 15 years. Costing was based on public 
sources. Only direct costs were considered in the calculation, including costs for treat-
ing severe adverse events and further treatment patterns. Costs were reported in 2010 
(US$1.00~$Brz1.8) Brazilian Reais and discounted at a 5% rate according to local 
guidelines for economic evaluation (Vianna 2007). RESULTS: R-FC combined 
therapy resulted in a gain of 1.031 life-years (Lys) (5.611 vs. 4.579) at an incremental 
cost of $Brz44,780. The ICER of R-FC versus FC is, therefore, estimated to be 
$Brz43,414 per LY gained. The probability of R-FC being cost-effective is 98.84%, 
considering a willingness-to-pay of R$100,000. CONCLUSIONS: In untreated CLL 
patients, R-FC therapy improves overall survival and progression-free survival com-
pared with FC alone. Results suggest that F-CR combined therapy is a cost-effective 
intervention for the Brazilian Public Healthcare System.
PCN71
A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID 
FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH 
BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN 
COUNTRIES
Botteman M1, Carter J1, Kaura S2
1Pharmerit North America, LLC, Bethesda, MD, USA; 2Novartis Pharmaceuticals 
Corporation, Florham Park, NJ, USA
OBJECTIVES: Zoledronic acid (ZOL) is the only bisphosphonate indicated for prevent-
ing skeletal-related events (SREs) in patients with bone metastases from prostate cancer 
(PC). We estimated and compared the cost-effectiveness of ZOL versus placebo for this 
indication in France, Germany, Portugal, and the The Netherlands. METHODS: Incre-
mental costs and quality-adjusted life-years (QALYs) associated with ZOL and placebo 
were estimated using a literature-based decision analytic model using data from a 
15-month randomized trial comparing ZOL (4 mg monthly; n = 214) with placebo (n 
= 208). The model included assumptions about SREs, mortality, drug and administration 
costs, SRE costs, quality of life, and therapy duration. SRE costs were estimated using 
Diagnosis Related Group tariff information (supplemented with published literature) in 
France and Germany, and published retrospective medical record review cost analyses 
in Portugal and the The Netherlands. RESULTS: Over 15 months, the cumulative 
projected SREs were 0.83 for ZOL and 1.66 for placebo. ZOL reduced SRE costs by 
c2659 to c4005, depending on the country. SRE cost savings were greatest in the The 
Netherlands, followed by Portugal, Germany, and France. ZOL reduced total costs 
(including drug costs) by c62 in Portugal and c301 in the The Netherlands, but increased 
costs by c562 in Germany and c1022 in France versus placebo. ZOL increased quality-
adjusted survival by 0.03566 QALY per patient, with an incremental cost per QALY 
gained versus placebo of c15,770 in Germany and c28,648 in France. In all countries, 
the cost-effectiveness ratio for ZOL was favorable and substantially below the interna-
tionally accepted c50,000/QALY threshold. Costs and QALYs were saved with ZOL 
in Portugal and the The Netherlands. CONCLUSIONS: In patients with bone metastasis 
from PC, ZOL is economically attractive. The cost-effectiveness ratio for ZOL is below 
standard cost-effectiveness thresholds used by most health-care systems. In Portugal and 
the The Netherlands, ZOL is cost-saving versus placebo.
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OBJECTIVES: The 74-month follow-up of the BIG 1–98 trial reported improved 
overall survival (OS) for 5 years letrozole (LET) versus tamoxifen (TAM; hazard ratio 
0.83; 95% CI 0.71, 0.97; P < 0.05). The 100-month follow-up of the ATAC trial did 
not show a signiﬁ cant difference in OS for anastrozole (ANA) versus TAM. Using 
reported differences in OS, we estimated the incremental cost per quality-adjusted 
life-year (QALY) gained for 5 years LET or ANA versus 5 years TAM in postmeno-
pausal women with endocrine-responsive breast cancer (ERBC), from a UK NHS 
perspective. METHODS: Annual survival probabilities postoperatively were extracted 
from BIG 1–98 and ATAC results. Survival was extrapolated to 20 years using data 
reported by the EBCTG for women receiving 5 years TAM. Conservatively, equivalent 
annual survival probabilities were assumed for TAM, LET, and ANA groups after 
follow-up. Published adverse event (AE) costs and 5-year costs for locoregional recur-
rence (LR) and metastases were applied. Published utility weights for disease-free 
survival with AEs, LR, and metastases were used. All costs and health beneﬁ ts were 
discounted at 3.5% annually. RESULTS: Over a 20-year period, the discounted 
additional treatment costs are £3618 for LET and £3736 for ANA. When accounting 
for AEs and reduced BC recurrence, the total cost difference between LET and TAM 
is £2964, and between ANA and TAM is £2929. The model estimated a difference in 
discounted QALYs of 0.297 for LET versus TAM, with an incremental cost per QALY 
gained of £9999. The incremental cost per QALY gained for ANA versus TAM is 
£46,829. CONCLUSIONS: Using updated OS data, economic analysis of 5 years LET 
or ANA versus 5 years TAM in postmenopausal women with ERBC suggests that LET 
is substantially more cost-effective than ANA. The current analysis is consistent with 
earlier extrapolations based on differences in time to recurrence.
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OBJECTIVES: The aim of a neurolytic sympathetic blockade is to reduce consumption 
or the side effects of opioids, to improve and enhance the analgesic response, and get 
efﬁ ciency of costs related to treatment. We assessed the cost-effectiveness (CEA) of 
superior hypogastric plexus inhibition (SHPI) in patients with cancer and visceral pain 
in the lower abdomen. METHODS: We conducted a CEA within a retrospective 
follow-up clinical study at the National Cancer Institute in Mexico City in patients 
>18 years with cancer and visceral pain. We assessed patients that underwent SHPI 
between March 2005 and June 2009. We evaluated the visual analog pain scale (VAS), 
drugs resource consumption, and medical direct costs. The measures were evaluated 
before and after (1 day, 1 week, 1, 2, 3, and 6 months) the procedure. Incremental 
cost-effectiveness ratio (ICER) was calculated. RESULTS: Twenty-six patients under-
went SHPI. They were matched with 26 patients with cancer and visceral pain 
managed with standard treatment (WHO analgesic ladder steps). The average cost per 
patient was not signiﬁ cantly different between treatment groups ($7372 vs. $6768 
MXP, P = 0.54); however, the effectiveness (treatment success: 50% decrease in drug 
consumption within 30 days) was much higher for SHPI (65% vs. 19%, P < 0.001). 
The ICER was $1308 (IC 95% 1104–1485) MXP per patient. CONCLUSIONS: SHPI 
was effective for treating visceral pain in cancer patients. The ICER ($1313 MXP) 
shows that SHPI is a cost-effectiveness alternative in Mexico (threshold of 1 GDP per 
capita).
